BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
2.380
-0.010 (-0.42%)
Nov 4, 2024, 4:00 PM EST - Market closed
BioCardia Employees
As of December 31, 2023, BioCardia had 20 total employees, including 16 full-time and 4 part-time employees. The number of employees decreased by 16 or -44.44% compared to the previous year.
Employees
20
Change (1Y)
-16
Growth (1Y)
-44.44%
Revenue / Employee
$21,400
Profits / Employee
-$427,950
Market Cap
8.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
XWELL | 337 |
Vaccinex | 40 |
Virax Biolabs Group | 17 |
Quantum BioPharma | 17 |
Edesa Biotech | 16 |
Soligenix | 15 |
TransCode Therapeutics | 10 |
Cardio Diagnostics Holdings | 9 |
BCDA News
- 6 weeks ago - BioCardia Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family - GlobeNewsWire
- 2 months ago - FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment - GlobeNewsWire
- 2 months ago - BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results - GlobeNewsWire
- 3 months ago - BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application - GlobeNewsWire
- 5 months ago - BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach - GlobeNewsWire